15 million J&J COVID Vaccines Thrown Away After Ingredient

New Post Public Reply Private Reply Replies (0) Message Board
wowhappens28
240
15 million J&J COVID Vaccines Thrown Away After Ingredient Mix-Up With AstraZeneca

https://childrenshealthdefense.org/defender/j...nt-mix-up/

Emergent has been cited repeatedly by the FDA for problems such as poorly trained employees, cracked vials and mold around one of its facilities, according to records obtained by the Associated Press through the Freedom of Information Act.

AstraZeneca and J&J’s COVID vaccines employ the same technology which uses a version of a virus — known as a vector — that is transmitted into cells to make a protein that then stimulates the immune system to produce antibodies.

However, J&J’s and AstraZeneca’s vectors are biologically different and not interchangeable.

Federal officials said Emergent’s mistake was human error that went undiscovered for days until J&J’s quality control checks uncovered it, according to people familiar with the situation. By then, up to 15 million doses had been contaminated, reported The Indian Express.

The error does not affect any J&J doses currently being distributed and administered in the U.S., as those were produced in the Netherlands where operations have been fully approved by federal regulators.

“As with the manufacturing of any complex biologic medication or vaccine, the start-up for a new process includes test runs and quality checks to ensure manufacturing is validated and the end product meets our high-quality standards,” J&J said in a statement Wednesday. “This approach includes having dedicated specialists on the ground at the companies that are part of our global manufacturing network to support safety and quality.”

Details of the issue were identified and addressed with Emergent and the FDA, J&J said.

An FDA spokesperson told news outlets: “FDA is aware of the situation, but we are unable to comment further. Questions about a firm’s manufacturing facilities should be directed to that firm.”

As reported by The Defender, J&J has never made a vaccine, but since entering the pharmaceutical market in 1959, the company has made a lot of headlines and has been fined billions of dollars for bad, including some illegal, behavior.

Developing a vaccine requires many years and necessitates the establishment of an R&D infrastructure vastly different than the structure required for conventional drug development. Yet the company was able to rush to market its first vaccine for a viral strain identified just 14 months ago.

J&J has a relationship with the Bill & Melinda Gates Foundation and the Global Alliance for Vaccines and Immunizations and has a $1 billion deal with the U.S. government to provide 100 million doses of its Emergency Use Authorization experimental vaccine.

According to the FDA, J&J’s vaccine consists of a “replication-incompetent recombinant adenovirus type 26, a SARS-CoV-2 spike protein, and contains the following inactive ingredients: citric acid monohydrate, trisodium citrate dihydrate, ethanol, 2-hydroxypropyl-β-cyclodextrin (HBCD), polysorbate 80, sodium chloride, sodium hydroxide and hydrochloric acid. The adenovirus is also grown in the PER.C6® aborted fetal cell line.

Polysorbate 80, an ingredient in J&J’s vaccine, is a suspected underlying cause of anaphylactic COVID vaccine adverse reactions. Studies show that polysorbate 80 disrupts the normally protective blood-brain barrier.

As The Defender Reported, the FDA authorized J&J’s single-dose COVID vaccine in late February with a reported overall efficacy rating of 66% for preventing “moderate to severe COVID-19.” The vaccine was only 42.3% effective about a month after getting the shot in people 60 or older who had comorbidities.

Although the FDA identified no safety concerns with J&J’s COVID vaccine, suspected vaccine injuries associated with the vaccine have been reported to the Vaccine Adverse Events Reporting System since March 2 — the primary mechanism for reporting adverse vaccine reactions in the U.S.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hidden Assets Guide: Essential Tool for Attorneys

Updated Category News Views 3

Asset Searches: Why They Matter to Lawyers Some days you just have to get into the nitty-gritty of legal legwork, and today feels like one of those days. Asset Search USA has come out swinging with a practical guide that no attorney should ignore, especially if they're dealing with the shadowy world of hidden assets. What are we talking about here? We're talking about...

Continue Reading
State Business Formation Trends: Key Insights for Investors

Updated Category News Views 4

Grasping New Business Formation Shifts The fresh ink isn't dry yet on the latest figures from Registered Agents Inc, revealing a surge in entrepreneurial spark throughout the U.S. September 2026 smashed records with over 562,579 new business registrations—the first time this month crossed the half-million threshold. Quite the feat, really, showcasing a 14% uptick from...

Continue Reading
Unicycive Faces Legal Heat Amid Stock Tumble

Updated Category News Views 2

Unicycive Therapeutics' Rough Ride In this wild market, sometimes even the most seasoned investors get blindsided. Unicycive Therapeutics (NASDAQ: UNC) shareholders are currently caught in a storm with their stock nose-diving by 39.1% on June 30, 2026. It's like being taken to the cleaners without the decency of a warning. Failed Expectations & FDA Blues Here's the...

Continue Reading
Callender Bowlin's Legal Eagles Soar in Texas 2026

Updated Category News Views 4

The Spotlight on CB Trial's Legal Titans Roll the dice, folks—who stands up in Texas’ legal playground? It's Callender Bowlin, PLLC's hotshots again securing their hallmark in the 2026 Texas Super Lawyers gauntlet. This ain’t their first rodeo, either. Founding partners Mark Callender and Josh Bowlin—names synonymous with high-stakes litigation—continue to bask...

Continue Reading
Autoliv Sees Mixed Q3 2026 Amid Global Challenges

Updated Category News Views 6

An Uneven Road: Autoliv's Q3 2026 Chronicle You'd think by now everyone in the automotive game would have mastered the art of the pivot. Well, Autoliv seems to have gotten the memo for Q3 2026. Sales dipped slightly, yet their moves in Asia hint at a calculated gambit in a rough global landscape. Digging into the Numbers The financials were a mixed bag. Net sales huddled...

Continue Reading
VoxNexus Debuts On-Device AI: A Game-Changer for Languages

Updated Category News Views 6

VoxNexus Changes the Game with VoxEdge Here's the rub with tech: it often feels like it's only for the folks who already have a leg up. VoxNexus just flipped the script with its new product, VoxEdge, an on-device voice stack that's making waves by breaking language barriers in the ever-evolving AI world. This move might just shift the landscape of voice artificial...

Continue Reading
Ziihera Extends Survival in Advanced GEA: Big Gains Ahead?

Updated Category News Views 5

A Hard Look at Ziihera's Three-Year Survival Story You know the drill—anytime a new drug pulls weight in the cancer arena, ears perk up. Jazz Pharmaceuticals' recent unveil at the 2026 ESMO Congress caught my attention like a solid run on the NASDAQ. We're looking at Ziihera, tangoing with tislelizumab and chemotherapy, hauling serious results against the nasty fight of...

Continue Reading
Ping An Good Doctor Grows 35%: AI's Expanding Role

Updated Category News Views 5

Ping An Good Doctor's Noteworthy Financial Uptick Stop me if you've heard this one: a hefty hike in numbers that make investors straighten up a bit. Ping An Good Doctor did just that, reporting a 35% spark in net profit as the books closed up till September 2026. In a landscape where many health-tech firms merely tread water, these guys rode a wave of RMB 0.25 billion in...

Continue Reading
Enigmata Innovates AI Security with Finovifi Tie-Up

Updated Category News Views 1

Emerging AI Risks and Protective Measures AI in financial spaces is like walking a tightrope, there's potential but caution is crucial. Enter Enigmata, diving headfirst into this arena by shaking hands with the Finovifi Marketplace. Their aim? To bolster AI's promise without letting sensitive data slip through the cracks. Sentinel: A New Guard for Sensitive Data Let's not...

Continue Reading
Unicoin’s 'RISE IN PINK' Blends Crypto and Charity

Updated Category News Views 1

The New Face of Charitable Giving: Crypto and Cause Turning the spotlight on how blockchain and altruism can mesh, Unicoin's latest campaign isn’t just your average philanthropic endeavor. With 'RISE IN PINK', they're out to change the game, blending digital assets with a deep human cause—breast cancer awareness and support. Technology Meets Human Cause Imagine...

Continue Reading

Top 5 Most Recently Viewed Articles

Essential Tips for Early Black Friday Cybersecurity Deals

Updated Category News Views 122

Cyber Advice Highlights Early Black Friday Savings in Cybersecurity As the holiday season approaches, many consumers are getting ready for the chaos that Black Friday brings. However, this year, the excitement kicks off earlier than ever, with enticing cybersecurity deals launched by Cyber Advice to meet the growing demand for online safety. With the rise of digital...

Continue Reading
Nayya Receives Investment from Workday Ventures for Growth

Updated Category News Views 95

Nayya's Strategic Investment Journey Nayya, a leading benefits experience platform, is thrilled to announce a new strategic investment from Workday Ventures. This development marks a crucial step in improving how employees select and engage with their benefits. The platform empowers users to make informed choices, ensuring they fully utilize their available options....

Continue Reading
Leadership Changes at Huize Holding Limited: A New Direction

Updated Category News Views 147

Resignation of an Independent Director at Huize Holding Limited In a recent announcement, Huize Holding Limited (NASDAQ: HUIZ), a prominent insurance technology platform in Asia, revealed the resignation of Mr. Aaron Xiaolei Hou from his role as an independent director of the company. Effective September 30, 2025, Mr. Hou's decision to step down is attributed to personal...

Continue Reading
Discover the Charm of Hubei Village in China

Updated Category News Views 129

Exploring the Heart of Hubei Village Imagine a journey through the serene rural landscapes of China, a picturesque escape that offers a glimpse into the everyday lives of its residents. Hubei Village, often referred to as the "Altay of Jiangxi," is an ideal destination for those seeking to experience the beauty of Chinese village life. This captivating village, nestled...

Continue Reading
Understanding Kohl's (KSS) Options Activity: A Deep Dive

Updated Category News Views 141

Unveiling the Intriguing Options Activity Surrounding Kohl's Recently, significant investments have emerged concerning Kohl's (KSS). High-stakes investors appear to be adopting a bullish outlook on the retail giant. This trend should certainly pique the interest of retail traders. Our analysis today reveals critical information drawn from publicly available options...

Continue Reading